EUVIMEDEUVIMED entdecken
Übersichtsarbeit

From Concept to Cure: The Road Ahead for Ruthenium‐Based Anticancer Drugs

Srividya Swaminathan iD, Jebiti Haribabu iD, Ramasamy Karvembu iD

ChemMedChem · 2024

DOI: 10.1002/cmdc.202400435 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift ChemMedChem, 2024. Verfasst von Srividya Swaminathan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Center for Computational Modelling, Chennai Institute of Technology, Chennai, Tamil Nadu, 600069, India. Hauptthemen laut MEDLINE: Antineoplastic Agents, Ruthenium, Neoplasms, Coordination Complexes. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 86 Literaturangaben. Gefördert von: Center for Computational Modeling at Chennai Institute of Technology (CIT), DST-INSPIRE, University of Atacama.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The evolution of chemotherapy, especially the dawn of metal‐based drugs, represents a transformative era in cancer treatment. From the serendipitous discovery of mustard gas's cytotoxic effects to the sophisticated development of targeted therapies, chemotherapy has significantly refined. Central to this progression is the incorporation of metal‐based compounds, such as platinum (Pt), ruthenium (Ru), and gold (Au), which offer unique mechanisms of action, distinguishing them from organic therapeutics. Among these, Ru complexes, exemplified by BOLD‐100 and TLD1433, have shown exceptional promise due to their selective activity, lower propensity for resistance, and the ability to target spescific cellular pathways. This paper explores the journey of such Ru candidates, focusing on the mechanisms, efficacy, and clinical potential of these Ru‐based drugs, which stand at the forefront of current research, aiming to provide more targeted, less toxic, and highly effective cancer treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsRutheniumNeoplasmsCoordination ComplexesHumansDrug Screening Assays, AntitumorMolecular StructureCell ProliferationOrganometallic CompoundsAnimals

Substanzen

Antineoplastic AgentsRutheniumCoordination ComplexesOrganometallic Compounds

Autor:innen und Institutionen

  • Center for Computational Modelling, Chennai Institute of Technology, Chennai, Tamil Nadu, 600069, India.
  • Inorganic and Physical Chemistry Laboratory, CSIR-CLRI, Chennai, Tamil Nadu, 600020, India.
  • Faculty of Medicine, University of Atacama, Los Carreras 1579, Copiapo, 1532502, Chile.
  • Department of Chemistry, National Institute of Technology, Tiruchirappalli, Tamil Nadu, 620015, India.

ORCID-Profile: Srividya Swaminathan, Jebiti Haribabu, Ramasamy Karvembu

Förderung

  • Center for Computational Modeling at Chennai Institute of Technology (CIT)
  • DST-INSPIRE
  • University of Atacama
  • DST-SERB
  • Universidad de Atacama

Zitieren

APA

Swaminathan, S., Haribabu, J., & Karvembu, R. (2024). From Concept to Cure: The Road Ahead for Ruthenium‐Based Anticancer Drugs. ChemMedChem. https://doi.org/10.1002/cmdc.202400435

Vancouver

Swaminathan S, Haribabu J, Karvembu R. From Concept to Cure: The Road Ahead for Ruthenium‐Based Anticancer Drugs. ChemMedChem. 2024. doi:10.1002/cmdc.202400435

BibTeX
@article{Swaminathan2024,
  author = {Swaminathan, Srividya and Haribabu, Jebiti and Karvembu, Ramasamy},
  title = {From Concept to Cure: The Road Ahead for Ruthenium‐Based Anticancer Drugs},
  journal = {ChemMedChem},
  year = {2024},
  doi = {10.1002/cmdc.202400435}
}
Kostenlos starten →